1-7 of 7
Berengere De Moucheron
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

BMS-986458, a first-in-class, bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6) in patients with Relapsed/Refractory (R/R) non-Hodgkin lymphoma (NHL): Updated results from the Phase 1 dose escalation study

Free
Franck Morschhauser, David Qualls, Jennifer Lue, Anastasios Stathis, Marcel Nijland, Avyakta Kallam, Jörg Bittenbring, Guillaume Cartron, Noémie Lang, Marjolein Van Der Poel, Loic Ysebaert, Vladan Vucinic, Alejandro Martin Garcia-Sancho, Antonio Rueda Dominguez, Noelia Purroy, Berengere De Moucheron, Xiaosong Li, Carla Guarinos, Joseph Burnett, Alicia Benítez Rondán, Michael Pourdehnad, Jessica Voetsch, Diego Sobradillo, Jean-Marie Michot
Journal: Blood
Blood (2025) 146 (Supplement 1): 480.
https://doi.org/10.1182/blood-2025-480
Published: 2025
Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Phase 1/2 study extended follow-up Results

Free
Marc Hoffmann, Julio Chavez, Jason Westin, Judit Jørgensen, Javier Munoz, Cecilia Carpio, Guilherme Perini, Emmanuel Bachy, Victoria Campbell, Caroline Hasselbalch Riley, Franck Morschhauser, Daniel Morillo, Alev Akyol, Berengere De Moucheron, Michael Pourdehnad, Akshay Sudhindra, Soraya Carrancio, Jessica Voetsch, Gang Yang, Serena Perna, Jean-Marie Michot
Journal: Blood
Blood (2025) 146 (Supplement 1): 479.
https://doi.org/10.1182/blood-2025-479
Published: 2025
Journal Articles

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results

Free
Julio Chavez, Jason Westin, Javier Munoz, Emmanuel Bachy, Judit Jørgensen, Guilherme Perini, Daniel Morillo, Abel Costa, Parth Rao, Berengere De Moucheron, Gang Yang, Soraya Carrancio, Akshay Sudhindra, Michael Pourdehnad, Jessica Voetsch, Serena Perna, Jean-Marie Michot
Journal: Blood
Blood (2025) 146 (Supplement 1): 1006.
https://doi.org/10.1182/blood-2025-1006
Published: 2025
Journal Articles

Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Free
Jean-Marie Michot, Franck Morschhauser, Silvia Ferrari, Judit Mészáros Jørgensen, Loretta Nastoupil, Emmanuel Bachy, Michael Pourdehnad, Akshay Sudhindra, Alev Akyol, Bérengère de Moucheron, Soraya Carrancio, Jessica Voetsch, Xirong Zheng, Julio C. Chavez
Journal: Blood
Blood (2024) 144 (Supplement 1): 869.
https://doi.org/10.1182/blood-2024-203163
Published: 2024
Journal Articles

Golcadomide (GOLCA) ± Rituximab (RTX) Demonstrates Durable Efficacy and Is Well Tolerated in Patients (pts) with Relapsed/Refractory Follicular Lymphoma (R/R FL): Updated Results from the Phase 1/2 CC-99282-NHL-001 Study

Free
Julio C. Chavez, Guilherme Fleury Perini, Loretta Nastoupil, Judit Mészáros Joergensen, Pierre Bories, Bijou Fontanet, Pier Luigi Zinzani, Javier Munoz, Daniel Morillo Giles, Cecilia Carpio, Abel Costa, Won Seog Kim, Parth Rao, Bérengère de Moucheron, Yang Gang, Carla Guarinos, Akshay Sudhindra, Michael Pourdehnad, Jean-Marie Michot
Journal: Blood
Blood (2024) 144 (Supplement 1): 3018.
https://doi.org/10.1182/blood-2024-203131
Published: 2024
Journal Articles

Cell-Intrinsic and Immune-Mediated Effects in Lymphoma Patients Treated with Golcadomide and Associations with Treatment Outcome

Free
Soraya Carrancio, Jessica Voetsch, Alberto Risueño, Carla Guarinos, Siddhesh Kulkarni, Mandeep Takhar, Matthew E. Stokes, Bérengère de Moucheron, Laura Furman, Julio C. Chavez, Jean-Marie Michot, Loretta Nastoupil, Daniel W. Pierce, Danielle Greenawalt, Michael Pourdehnad
Journal: Blood
Blood (2024) 144 (Supplement 1): 3104.
https://doi.org/10.1182/blood-2024-203139
Published: 2024
Journal Articles

Efficacy and Safety of Golcadomide, a Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, Combined with Rituximab in a Phase 1/2 Open-Label Study of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Free
Julio C. Chavez, Loretta J. Nastoupil, Franck Morschhauser, Guillaume Cartron, Judit Mészáros Joergensen, Emmanuel Bachy, Pierre Bories, Victoria Campbell, Bijou Fontanet, Poliana P. Patah, Bérengère de Moucheron, Soraya Carrancio, Xirong Zheng, Chaoqun Mei, Michael Pourdehnad, Jean-Marie Michot
Journal: Blood
Blood (2023) 142 (Supplement 1): 4496.
https://doi.org/10.1182/blood-2023-188771
Published: 2023